Literature DB >> 25218820

HERG-targeted therapy in both cancer and cardiovascular system with cardiovascular drugs.

Salvatore Patanè1.   

Abstract

Entities:  

Keywords:  Cancer chemotherapy; Cardio-oncology; Cardiotoxicity; HERG; Multidrug resistance (MDR); Torsade de pointes arrhythmia(TdP)

Mesh：

Substances：

Year:  2014        PMID： 25218820     DOI： 10.1016/j.ijcard.2014.07.129

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  4 in total

Review 1.  Insights into cardio-oncology: Polypharmacology of quinazoline-based α1-adrenoceptor antagonists.

Authors:  Salvatore Patanè
Journal:  World J Cardiol       Date:  2015-05-26

2.  MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation.

Authors:  Abdullah A Assiri; Noha Mourad; Minghai Shao; Patrick Kiel; Wanqing Liu; Todd C Skaar; Brian R Overholser
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

3.  Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer.

Authors:  Sergey A Dyshlovoy; Katharina Otte; Winfried H Alsdorf; Jessica Hauschild; Tobias Lange; Simone Venz; Christiane K Bauer; Robert Bähring; Kerstin Amann; Ramin Mandanchi; Udo Schumacher; Jennifer Schröder-Schwarz; Tatyana N Makarieva; Alla G Guzii; Kseniya M Tabakmakher; Sergey N Fedorov; Larisa K Shubina; Igor E Kasheverov; Heimo Ehmke; Thomas Steuber; Valentin A Stonik; Carsten Bokemeyer; Friedemann Honecker; Gunhild von Amsberg
Journal:  Oncotarget       Date:  2016-10-25

4.  hERG1 is involved in the pathophysiological process and inhibited by berberine in SKOV3 cells.

Authors:  Duo Zhi; Kun Zhou; Dahai Yu; Xiaofan Fan; Juan Zhang; Xiang Li; Mei Dong
Journal:  Oncol Lett       Date:  2019-04-17       Impact factor: 2.967
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.